SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

baloncibart

REGN·REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
At least 4-6 years away, if successful. Both Phase 2 trials are complete but results have not been disclosed, and no Phase 3 trials have been registered. The drug would need positive Phase 2 data, Phase 3 trials, and FDA review before any potential approval.
Why 3/10
No hard, dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled within the next ~12 months. Both Phase 2 trials have completed but results have not been disclosed, and no Phase 3 trials are registered. Baloncibart is a mid-stage program at a large-cap biotech ($86B market cap) with many approved products and higher-priority pipeline assets, so even a data readout would have limited stock impact.
Actionable Insight NEUTRAL

Watch for potential disclosure of Phase 2 topline results from either the POTS (PINNACLE) or sepsis (ESTELLA) trial, possibly at a future medical conference or in Regeneron's quarterly earnings materials. Positive results could support advancement to Phase 3, but given Regeneron's size and pipeline breadth, even a clear readout is unlikely to move the stock more than a few percent.

Price Chart

Loading chart...

Executive Summary

Baloncibart (REGN7544) is Regeneron's first-in-class monoclonal antibody that blocks NPR1 to raise blood pressure, being studied in Phase 2 for Postural Orthostatic Tachycardia Syndrome (POTS) and sepsis-induced hypotension. Both Phase 2 trials have completed enrollment and data collection (the POTS PINNACLE trial finished July 2026; the sepsis ESTELLA trial finished April 2026), but Regeneron has not publicly disclosed any topline results. Phase 1 data showed the drug was well-tolerated and durably raised blood pressure by 5-10 mmHg. For a non-medical investor, this is an early-stage pipeline asset at a large-cap biotech with many approved blockbusters (Dupixent, EYLEA HD, Libtayo), meaning baloncibart is a negligible part of Regeneron's valuation with no imminent binary catalyst.

How It Works

Baloncibart is a first-in-class injectable monoclonal antibody that blocks natriuretic peptide receptor 1 (NPR1), a protein involved in regulating blood pressure and fluid balance. By blocking NPR1, the drug aims to raise blood pressure and increase blood volume, which could help patients with conditions characterized by chronic low blood pressure and insufficient blood volume.

Trial Status

Two Phase 2 trials have both completed. The PINNACLE trial (NCT06593600) evaluated a single dose of REGN7544 versus placebo in 82 adults with Postural Orthostatic Tachycardia Syndrome (POTS) across the US and Canada; it started November 2024 and completed July 8, 2026. The ESTELLA trial (NCT06608901) evaluated REGN7544 in 76 patients with sepsis-induced hypotension across the US and France; it completed April 28, 2026. Neither trial has publicly disclosed topline results. A Phase 1 study in healthy adults (NCT05970718) showed the drug was generally well-tolerated and durably increased blood pressure by 5-10 mmHg.

The Two-Sided Case

▲ Bull Case4
First-in-class mechanism targeting NPR1, a novel approach for hypotensive disorders with no approved therapies specifically for POTS
Phase 1 data showed durable blood pressure increases of 5-10 mmHg with good tolerability, supporting the mechanism
Both Phase 2 trials have completed enrollment and data collection, meaning results could be disclosed at any time
POTS market is growing (estimated $350M in 2025, projected to reach $720M by 2033 per one estimate), driven by post-COVID cases
▼ Bear Case4
Both Phase 2 trials completed months ago (April and July 2026) but Regeneron has not disclosed any topline results, which could suggest underwhelming efficacy
Baloncibart is a very small program within Regeneron's massive pipeline (Dupixent, EYLEA HD, Libtayo, cemdisiran, etc.), so even positive data would have minimal impact on the stock
No Phase 3 trials registered, meaning the drug is likely years away from any potential approval or regulatory catalyst
The sepsis-induced hypotension indication faces a challenging clinical trial environment with high placebo response rates and difficult endpoints

Upcoming Catalysts

  • Disclosure of Phase 2 topline results for the POTS (PINNACLE) trial or the sepsis-induced hypotension (ESTELLA) trial, possibly at a future medical conference
  • Decision by Regeneron on whether to advance baloncibart to Phase 3 development

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report

Sources · 14

Hover a chip for the title
1 synapse.patsnap.com2 adisinsight.springer.com3 biopharmawatch.com4 trialticker.com5 adisinsight.springer.com6 adisinsight.springer.com7 ahajournals.org8 clinicaltrials.gov9 clinicaltrials.gov10 medchemexpress.com11 delta.larvol.com12 regeneron.com13 investor.regeneron.com14 verifiedmarketresearch.com